Tafamidis meglumine
Tafamidis meglumine (Vyndaqel, Fx-1006A) stabilizes the tetrameric structure of transthyretin (TTR) by binding to thyroxine-binding sites. Tafamidis meglumine treats transthyretin familial amyloid polyneuropathies (TTR-FAP), a condition characterized by neurological damage from TTR amyloidosis, by preventing the misfolding and aggregation of transthyretin (TTR) into amyloid fibrils.
| Trivial name | Vyndaqel, Fx-1006A |
| Catalog Number | E4852 |
| Molecular Formula | C34H34F2N4O6 |
| CAS# | 951395-08-7 |
| Inchi | InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2 ,1H3,(H,38,41)(H,39,42) |
| Inchi Key | CXQHYVUVSFXTMY-UHFFFAOYSA-N |
| SMILES | COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F |
| Size | 5mg |
| Supplier Page | http://www.selleckchem.com/products/tafamidis-meglumine.html |
| Additional Information | https://file.selleck.cn/downloads/struct/E4852-Tafamidis-meglumine-chemical-structure.png |